Subramanian J, Regenbogen T, Nagaraj G, Lane A, Devarakonda S, Zhou G F, & Govindan R. (2013). Review of Ongoing Clinical Trials in Non-Small-Cell Lung Cancer A Status Report for 2012 from the ClinicalTrialsgov Web Site. Journal of Thoracic Oncology, 8(7), 860-865. ( 7/2013 - Present )
Introduction: Clinical research in non-small-cell lung cancer (NSCLC) is a rapidly evolving field. In an effort to identify the current trends in lung cancer clinical research, we reviewed ongoing clinical trials in NSCLC listed in the registry in 2012, and we also compared this data to a similar survey conducted by us in 2009. Methods: The Web site's advanced search function was used to search for the term non-small cell lung cancer. The search was further refined by using the following options from the search page drop-down menu, open studies and interventional. Studies with non-NSCLC tumor histologies and pediatric studies were excluded. Results: Of the 477 trials included in the analysis, 105 (22.0%) were phase I, 223 phase II (46.8%), and 63 phase III trials (13.2%). When compared with data from 2009, university-sponsored trials decreased in number (45.4%-34.2%; p < 0.001) whereas industry-sponsored trials remained almost the same. There was a significant increase in trials conducted exclusively outside of the United States (35.9%-48.8%; p = 0.001). The number of studies with locations in China (61, 12.8%) was second only to that in the United States (244, 51.2%). Studies reporting biomarker analysis increased significantly from 37.5% to 49.1% in 2012 (p < 0.001). Biomarker-based patient selection also increased significantly from 7.9% to 25.8% (p < 0.001). Targeted therapies were evaluated in 70.6% of phase I/II and II trials, and the most common class of targeted agent studied was epidermal growth factor receptor tyrosine kinase inhibitors (38.0%). Prespecified accrual times were observed to increase when compared with data reported in 2009, especially among industry-sponsored studies. Conclusions: Our survey identified major changes in lung cancer clinical research since 2009. Almost half of all studies registered at the Web site are being conducted outside the United States, and several novel molecularly targeted agents are being evaluated in the treatment of patients with NSCLC. More importantly, we identified a threefold increase in the number of studies that perform biomarker testing to determine patient selection over the last 3 years.